Abstract |
The hypolipidemic and antiatherosclerotic effects of a novel acyl CoA:cholesterol acyltransferase (ACAT) inhibitor, HL-004, were studied in stroke-prone spontaneously hypertensive rats (SHRSP). SHRSP were administered 0.01-0.09% HL-004 mixed in a hypercholesterolemic (HC) diet for 50 days. HL-004 reduced the cholesterol and triglyceride levels in serum, as well as those in the liver, small intestine, and aorta, in a dose-dependent manner. HC diet-induced severe fat deposition in the mesenteric arteries, which is characteristic of SHRSP, was also decreased by HL-004. The ACAT activity of the small intestine and liver was decreased by HL-004. In particular, liver ACAT activity was significantly low in SHRSP given 0.09% HL-004, compared to that of normal animals. These results suggest that HL-004 is a systemic ACAT inhibitor and that the ACAT inhibition in the intestine, liver, and aorta is involved in the hypolipidemic and antiatherosclerotic effects of HL-004.
|
Authors | S Murakami, Y Nara, Y Yamori |
Journal | Experimental and molecular pathology
(Exp Mol Pathol)
Vol. 63
Issue 1
Pg. 23-32
(Aug 1995)
ISSN: 0014-4800 [Print] Netherlands |
PMID | 8759051
(Publication Type: Journal Article)
|
Chemical References |
- Acetanilides
- Anticholesteremic Agents
- Fats
- HL 004
- Cholesterol
- Sterol O-Acyltransferase
|
Topics |
- Acetanilides
(pharmacology)
- Animals
- Anticholesteremic Agents
(therapeutic use)
- Cerebrovascular Disorders
(genetics)
- Cholesterol
(blood, metabolism)
- Disease Susceptibility
- Enzyme Activation
(drug effects)
- Fats
(metabolism)
- Hyperlipidemias
(drug therapy)
- Male
- Rats
- Rats, Inbred SHR
- Sterol O-Acyltransferase
(antagonists & inhibitors, drug effects)
- Tissue Distribution
(drug effects)
|